Phenotypic and molecular characterization of Streptococcus pneumoniae serotype 3 isolates from blood and respiratory samples in Canada: CANWARD 2007–21

Abstract Background Lower respiratory infections and invasive disease caused by Streptococcus pneumoniae serotype 3 remain major clinical challenges around the world, despite widespread availability of updated vaccines. Methods As part of CANWARD, antimicrobial susceptibility testing and serotyping...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of antimicrobial chemotherapy 2024-10, Vol.79 (10), p.2653-2661
Hauptverfasser: Schellenberg, John J, Adam, Heather J, Baxter, Melanie R, Karlowsky, James A, Golden, Alyssa R, Martin, Irene, Zhanel, George G
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2661
container_issue 10
container_start_page 2653
container_title Journal of antimicrobial chemotherapy
container_volume 79
creator Schellenberg, John J
Adam, Heather J
Baxter, Melanie R
Karlowsky, James A
Golden, Alyssa R
Martin, Irene
Zhanel, George G
description Abstract Background Lower respiratory infections and invasive disease caused by Streptococcus pneumoniae serotype 3 remain major clinical challenges around the world, despite widespread availability of updated vaccines. Methods As part of CANWARD, antimicrobial susceptibility testing and serotyping were performed on all S. pneumoniae isolates from 2007 to 2021. A subset of 226/264 (85.6%) serotype 3 isolates were selected for WGS to determine sequence type (ST)/clonal cluster (CC) and correspondence of antimicrobial resistance determinants (erm, mefAE, tetM, cat, folA, folP) with resistance phenotype. Results Of the 3,039 S. pneumoniae isolates obtained from 2007 to 2021, 8.7% (n = 264) were serotype 3, with 64.0% of respiratory origin and 36.0% from blood. Of 226 sequenced serotype 3 isolates, 184 (81.4%) were ST180 (GPSC12). The proportion of ST8561 (single locus variant of ST180) increased from 7.2% to 16.6% during the study period. An increasing proportion of serotype 3 isolates had phenotypic resistance (P = 0.0007) and genetic resistance determinants (P = 0.004), comparing 2017–21 to 2007–11, largely due to a recently expanded ST180 clade with cat, tetM and mef determinants. Conclusions S. pneumoniae serotype 3 from GPSC12 continues to dominate throughout Canada, with an increase in the proportion of ST8561. The proportion of serotype 3 isolates that are phenotypically resistant and with genetic resistance determinants is increasing over time, reflecting a global increase in GPSC12 genotypes with known resistance determinants. Phylogenomic characterization of isolates collected over time and from around the world may facilitate improved treatment and enhanced prevention strategies, including new vaccines with activity against S. pneumoniae serotype 3.
doi_str_mv 10.1093/jac/dkae272
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11442004</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jac/dkae272</oup_id><sourcerecordid>3087357400</sourcerecordid><originalsourceid>FETCH-LOGICAL-c301t-585a902cf58a0ab58dcd48486de6b4067bd7fb6e691a8a0d7a5549959808ddb33</originalsourceid><addsrcrecordid>eNp9kT2P1DAQQC0E4paDih65Qkgo3Di2k5gGrZbjQzoB4kOU1sR2WB-JHezkpKXiP1Dx9_gl5NjlBA3VFPP0ZqRHyF0GjxgofnKO5sR-RlfW5TWyYqKCogTFrpMVcJBFLSQ_IrdyPgeASlbNTXLEFahSNWxFfrzZuhCn3egNxWDpEHtn5h4TNVtMaCaX_FecfAw0dvTdlNw4RRONmTMdg5uHGDw6ml26lDjKqc-xx8ll2qU40LaP0f42J5dHn3CKaUczDmO_ID7QDQa0-Jhu1q8-rt8-pSVA_fPb95LdJjc67LO7c5jH5MOz0_ebF8XZ6-cvN-uzwnBgUyEbiQpK08kGAVvZWGNFI5rKuqoVUNWtrbu2cpViuBC2RimFUlI10Fjbcn5Mnuy949wOzhoXpoS9HpMfMO10RK__3QS_1Z_ihWZMiOVbsRgeHAwpfpldnvTgs3F9j8HFOWsOTc1lLQAW9OEeNSnmnFx3dYeBvqypl5r6UHOh7_392hX7J98C3N8DcR7_a_oFx06s8Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3087357400</pqid></control><display><type>article</type><title>Phenotypic and molecular characterization of Streptococcus pneumoniae serotype 3 isolates from blood and respiratory samples in Canada: CANWARD 2007–21</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Schellenberg, John J ; Adam, Heather J ; Baxter, Melanie R ; Karlowsky, James A ; Golden, Alyssa R ; Martin, Irene ; Zhanel, George G</creator><creatorcontrib>Schellenberg, John J ; Adam, Heather J ; Baxter, Melanie R ; Karlowsky, James A ; Golden, Alyssa R ; Martin, Irene ; Zhanel, George G</creatorcontrib><description>Abstract Background Lower respiratory infections and invasive disease caused by Streptococcus pneumoniae serotype 3 remain major clinical challenges around the world, despite widespread availability of updated vaccines. Methods As part of CANWARD, antimicrobial susceptibility testing and serotyping were performed on all S. pneumoniae isolates from 2007 to 2021. A subset of 226/264 (85.6%) serotype 3 isolates were selected for WGS to determine sequence type (ST)/clonal cluster (CC) and correspondence of antimicrobial resistance determinants (erm, mefAE, tetM, cat, folA, folP) with resistance phenotype. Results Of the 3,039 S. pneumoniae isolates obtained from 2007 to 2021, 8.7% (n = 264) were serotype 3, with 64.0% of respiratory origin and 36.0% from blood. Of 226 sequenced serotype 3 isolates, 184 (81.4%) were ST180 (GPSC12). The proportion of ST8561 (single locus variant of ST180) increased from 7.2% to 16.6% during the study period. An increasing proportion of serotype 3 isolates had phenotypic resistance (P = 0.0007) and genetic resistance determinants (P = 0.004), comparing 2017–21 to 2007–11, largely due to a recently expanded ST180 clade with cat, tetM and mef determinants. Conclusions S. pneumoniae serotype 3 from GPSC12 continues to dominate throughout Canada, with an increase in the proportion of ST8561. The proportion of serotype 3 isolates that are phenotypically resistant and with genetic resistance determinants is increasing over time, reflecting a global increase in GPSC12 genotypes with known resistance determinants. Phylogenomic characterization of isolates collected over time and from around the world may facilitate improved treatment and enhanced prevention strategies, including new vaccines with activity against S. pneumoniae serotype 3.</description><identifier>ISSN: 0305-7453</identifier><identifier>ISSN: 1460-2091</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/dkae272</identifier><identifier>PMID: 39092981</identifier><language>eng</language><publisher>UK: Oxford University Press</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents - pharmacology ; Canada - epidemiology ; Child ; Child, Preschool ; Drug Resistance, Bacterial - genetics ; Female ; Genotype ; Humans ; Infant ; Male ; Microbial Sensitivity Tests ; Middle Aged ; Multilocus Sequence Typing ; Original Research ; Phenotype ; Pneumococcal Infections - epidemiology ; Pneumococcal Infections - microbiology ; Respiratory Tract Infections - epidemiology ; Respiratory Tract Infections - microbiology ; Serogroup ; Serotyping ; Streptococcus pneumoniae - classification ; Streptococcus pneumoniae - drug effects ; Streptococcus pneumoniae - genetics ; Streptococcus pneumoniae - isolation &amp; purification ; Whole Genome Sequencing ; Young Adult</subject><ispartof>Journal of antimicrobial chemotherapy, 2024-10, Vol.79 (10), p.2653-2661</ispartof><rights>The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. 2024</rights><rights>The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c301t-585a902cf58a0ab58dcd48486de6b4067bd7fb6e691a8a0d7a5549959808ddb33</cites><orcidid>0000-0002-3238-0082 ; 0000-0002-1788-1794</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,1584,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39092981$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schellenberg, John J</creatorcontrib><creatorcontrib>Adam, Heather J</creatorcontrib><creatorcontrib>Baxter, Melanie R</creatorcontrib><creatorcontrib>Karlowsky, James A</creatorcontrib><creatorcontrib>Golden, Alyssa R</creatorcontrib><creatorcontrib>Martin, Irene</creatorcontrib><creatorcontrib>Zhanel, George G</creatorcontrib><title>Phenotypic and molecular characterization of Streptococcus pneumoniae serotype 3 isolates from blood and respiratory samples in Canada: CANWARD 2007–21</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>Abstract Background Lower respiratory infections and invasive disease caused by Streptococcus pneumoniae serotype 3 remain major clinical challenges around the world, despite widespread availability of updated vaccines. Methods As part of CANWARD, antimicrobial susceptibility testing and serotyping were performed on all S. pneumoniae isolates from 2007 to 2021. A subset of 226/264 (85.6%) serotype 3 isolates were selected for WGS to determine sequence type (ST)/clonal cluster (CC) and correspondence of antimicrobial resistance determinants (erm, mefAE, tetM, cat, folA, folP) with resistance phenotype. Results Of the 3,039 S. pneumoniae isolates obtained from 2007 to 2021, 8.7% (n = 264) were serotype 3, with 64.0% of respiratory origin and 36.0% from blood. Of 226 sequenced serotype 3 isolates, 184 (81.4%) were ST180 (GPSC12). The proportion of ST8561 (single locus variant of ST180) increased from 7.2% to 16.6% during the study period. An increasing proportion of serotype 3 isolates had phenotypic resistance (P = 0.0007) and genetic resistance determinants (P = 0.004), comparing 2017–21 to 2007–11, largely due to a recently expanded ST180 clade with cat, tetM and mef determinants. Conclusions S. pneumoniae serotype 3 from GPSC12 continues to dominate throughout Canada, with an increase in the proportion of ST8561. The proportion of serotype 3 isolates that are phenotypically resistant and with genetic resistance determinants is increasing over time, reflecting a global increase in GPSC12 genotypes with known resistance determinants. Phylogenomic characterization of isolates collected over time and from around the world may facilitate improved treatment and enhanced prevention strategies, including new vaccines with activity against S. pneumoniae serotype 3.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Canada - epidemiology</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Drug Resistance, Bacterial - genetics</subject><subject>Female</subject><subject>Genotype</subject><subject>Humans</subject><subject>Infant</subject><subject>Male</subject><subject>Microbial Sensitivity Tests</subject><subject>Middle Aged</subject><subject>Multilocus Sequence Typing</subject><subject>Original Research</subject><subject>Phenotype</subject><subject>Pneumococcal Infections - epidemiology</subject><subject>Pneumococcal Infections - microbiology</subject><subject>Respiratory Tract Infections - epidemiology</subject><subject>Respiratory Tract Infections - microbiology</subject><subject>Serogroup</subject><subject>Serotyping</subject><subject>Streptococcus pneumoniae - classification</subject><subject>Streptococcus pneumoniae - drug effects</subject><subject>Streptococcus pneumoniae - genetics</subject><subject>Streptococcus pneumoniae - isolation &amp; purification</subject><subject>Whole Genome Sequencing</subject><subject>Young Adult</subject><issn>0305-7453</issn><issn>1460-2091</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><sourceid>EIF</sourceid><recordid>eNp9kT2P1DAQQC0E4paDih65Qkgo3Di2k5gGrZbjQzoB4kOU1sR2WB-JHezkpKXiP1Dx9_gl5NjlBA3VFPP0ZqRHyF0GjxgofnKO5sR-RlfW5TWyYqKCogTFrpMVcJBFLSQ_IrdyPgeASlbNTXLEFahSNWxFfrzZuhCn3egNxWDpEHtn5h4TNVtMaCaX_FecfAw0dvTdlNw4RRONmTMdg5uHGDw6ml26lDjKqc-xx8ll2qU40LaP0f42J5dHn3CKaUczDmO_ID7QDQa0-Jhu1q8-rt8-pSVA_fPb95LdJjc67LO7c5jH5MOz0_ebF8XZ6-cvN-uzwnBgUyEbiQpK08kGAVvZWGNFI5rKuqoVUNWtrbu2cpViuBC2RimFUlI10Fjbcn5Mnuy949wOzhoXpoS9HpMfMO10RK__3QS_1Z_ihWZMiOVbsRgeHAwpfpldnvTgs3F9j8HFOWsOTc1lLQAW9OEeNSnmnFx3dYeBvqypl5r6UHOh7_392hX7J98C3N8DcR7_a_oFx06s8Q</recordid><startdate>20241001</startdate><enddate>20241001</enddate><creator>Schellenberg, John J</creator><creator>Adam, Heather J</creator><creator>Baxter, Melanie R</creator><creator>Karlowsky, James A</creator><creator>Golden, Alyssa R</creator><creator>Martin, Irene</creator><creator>Zhanel, George G</creator><general>Oxford University Press</general><scope>TOX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3238-0082</orcidid><orcidid>https://orcid.org/0000-0002-1788-1794</orcidid></search><sort><creationdate>20241001</creationdate><title>Phenotypic and molecular characterization of Streptococcus pneumoniae serotype 3 isolates from blood and respiratory samples in Canada: CANWARD 2007–21</title><author>Schellenberg, John J ; Adam, Heather J ; Baxter, Melanie R ; Karlowsky, James A ; Golden, Alyssa R ; Martin, Irene ; Zhanel, George G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c301t-585a902cf58a0ab58dcd48486de6b4067bd7fb6e691a8a0d7a5549959808ddb33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Canada - epidemiology</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Drug Resistance, Bacterial - genetics</topic><topic>Female</topic><topic>Genotype</topic><topic>Humans</topic><topic>Infant</topic><topic>Male</topic><topic>Microbial Sensitivity Tests</topic><topic>Middle Aged</topic><topic>Multilocus Sequence Typing</topic><topic>Original Research</topic><topic>Phenotype</topic><topic>Pneumococcal Infections - epidemiology</topic><topic>Pneumococcal Infections - microbiology</topic><topic>Respiratory Tract Infections - epidemiology</topic><topic>Respiratory Tract Infections - microbiology</topic><topic>Serogroup</topic><topic>Serotyping</topic><topic>Streptococcus pneumoniae - classification</topic><topic>Streptococcus pneumoniae - drug effects</topic><topic>Streptococcus pneumoniae - genetics</topic><topic>Streptococcus pneumoniae - isolation &amp; purification</topic><topic>Whole Genome Sequencing</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schellenberg, John J</creatorcontrib><creatorcontrib>Adam, Heather J</creatorcontrib><creatorcontrib>Baxter, Melanie R</creatorcontrib><creatorcontrib>Karlowsky, James A</creatorcontrib><creatorcontrib>Golden, Alyssa R</creatorcontrib><creatorcontrib>Martin, Irene</creatorcontrib><creatorcontrib>Zhanel, George G</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schellenberg, John J</au><au>Adam, Heather J</au><au>Baxter, Melanie R</au><au>Karlowsky, James A</au><au>Golden, Alyssa R</au><au>Martin, Irene</au><au>Zhanel, George G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phenotypic and molecular characterization of Streptococcus pneumoniae serotype 3 isolates from blood and respiratory samples in Canada: CANWARD 2007–21</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>2024-10-01</date><risdate>2024</risdate><volume>79</volume><issue>10</issue><spage>2653</spage><epage>2661</epage><pages>2653-2661</pages><issn>0305-7453</issn><issn>1460-2091</issn><eissn>1460-2091</eissn><abstract>Abstract Background Lower respiratory infections and invasive disease caused by Streptococcus pneumoniae serotype 3 remain major clinical challenges around the world, despite widespread availability of updated vaccines. Methods As part of CANWARD, antimicrobial susceptibility testing and serotyping were performed on all S. pneumoniae isolates from 2007 to 2021. A subset of 226/264 (85.6%) serotype 3 isolates were selected for WGS to determine sequence type (ST)/clonal cluster (CC) and correspondence of antimicrobial resistance determinants (erm, mefAE, tetM, cat, folA, folP) with resistance phenotype. Results Of the 3,039 S. pneumoniae isolates obtained from 2007 to 2021, 8.7% (n = 264) were serotype 3, with 64.0% of respiratory origin and 36.0% from blood. Of 226 sequenced serotype 3 isolates, 184 (81.4%) were ST180 (GPSC12). The proportion of ST8561 (single locus variant of ST180) increased from 7.2% to 16.6% during the study period. An increasing proportion of serotype 3 isolates had phenotypic resistance (P = 0.0007) and genetic resistance determinants (P = 0.004), comparing 2017–21 to 2007–11, largely due to a recently expanded ST180 clade with cat, tetM and mef determinants. Conclusions S. pneumoniae serotype 3 from GPSC12 continues to dominate throughout Canada, with an increase in the proportion of ST8561. The proportion of serotype 3 isolates that are phenotypically resistant and with genetic resistance determinants is increasing over time, reflecting a global increase in GPSC12 genotypes with known resistance determinants. Phylogenomic characterization of isolates collected over time and from around the world may facilitate improved treatment and enhanced prevention strategies, including new vaccines with activity against S. pneumoniae serotype 3.</abstract><cop>UK</cop><pub>Oxford University Press</pub><pmid>39092981</pmid><doi>10.1093/jac/dkae272</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-3238-0082</orcidid><orcidid>https://orcid.org/0000-0002-1788-1794</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0305-7453
ispartof Journal of antimicrobial chemotherapy, 2024-10, Vol.79 (10), p.2653-2661
issn 0305-7453
1460-2091
1460-2091
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11442004
source MEDLINE; Oxford University Press Journals All Titles (1996-Current)
subjects Adolescent
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents - pharmacology
Canada - epidemiology
Child
Child, Preschool
Drug Resistance, Bacterial - genetics
Female
Genotype
Humans
Infant
Male
Microbial Sensitivity Tests
Middle Aged
Multilocus Sequence Typing
Original Research
Phenotype
Pneumococcal Infections - epidemiology
Pneumococcal Infections - microbiology
Respiratory Tract Infections - epidemiology
Respiratory Tract Infections - microbiology
Serogroup
Serotyping
Streptococcus pneumoniae - classification
Streptococcus pneumoniae - drug effects
Streptococcus pneumoniae - genetics
Streptococcus pneumoniae - isolation & purification
Whole Genome Sequencing
Young Adult
title Phenotypic and molecular characterization of Streptococcus pneumoniae serotype 3 isolates from blood and respiratory samples in Canada: CANWARD 2007–21
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T18%3A13%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phenotypic%20and%20molecular%20characterization%20of%20Streptococcus%20pneumoniae%20serotype%203%20isolates%20from%20blood%20and%20respiratory%20samples%20in%20Canada:%20CANWARD%202007%E2%80%9321&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Schellenberg,%20John%20J&rft.date=2024-10-01&rft.volume=79&rft.issue=10&rft.spage=2653&rft.epage=2661&rft.pages=2653-2661&rft.issn=0305-7453&rft.eissn=1460-2091&rft_id=info:doi/10.1093/jac/dkae272&rft_dat=%3Cproquest_pubme%3E3087357400%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3087357400&rft_id=info:pmid/39092981&rft_oup_id=10.1093/jac/dkae272&rfr_iscdi=true